kevin, Author at Agendia Inc.

Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification
Gallery
Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification

Evidence

Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification

PUBLICATION: SABCS 2020 AUTHORS: Pat Whitworth, James V Pellicane, Jr., Read More

kevin2020-12-29T08:46:42-08:00December 29th, 2020|Evidence|

The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stagebreast cancer
Gallery
The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stagebreast cancer

Evidence, Uncategorized

The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stagebreast cancer

PUBLICATION: SABCS 2020 AUTHORS: Laura Lee, Sami Diab, Julie Barone, Read More

kevin2020-12-29T08:32:41-08:00December 29th, 2020|Evidence, Uncategorized|

Using BluePrint to elucidate the molecular heterogeneity of triple negative breast cancers
Gallery
Using BluePrint to elucidate the molecular heterogeneity of triple negative breast cancers

Evidence

Using BluePrint to elucidate the molecular heterogeneity of triple negative breast cancers

PUBLICATION: SABCS 2020 AUTHORS: Virginia G. Kaklamani, Cathy Graham, Karen Read More

kevin2020-12-29T08:24:36-08:00December 29th, 2020|Evidence|

Updated Outcome and Treatment Benefit Data from MINDACT Study Reinforce Real-World Value of MammaPrint for Clinical Low Risk Breast Cancer Patients at SABCS 2020

IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 11, 2020 Read More

kevin2020-12-11T06:45:15-08:00December 11th, 2020|News|

5-year outcomes in the NBRST trial: preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival

PUBLICATION: SABCS 2020 AUTHORS: Pat Whitworth, James V Pellicane, Read More

kevin2021-03-08T16:18:56-08:00December 10th, 2020|Evidence, Uncategorized|

The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in older patients
The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in older patients

Evidence, Uncategorized

The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in older patients

PUBLICATION: SABCS 2020 AUTHORS:Iris Noordhoek, Esther Bastiaannet, Ersan Lujinovic, Laura Read More

kevin2021-03-08T16:26:00-08:00December 10th, 2020|Evidence, Uncategorized|

Agendia Spotlight Poster at SABCS 2020 Confirms Pre-Operative Utility of MammaPrint and BluePrint

Clinical utility of molecular subtyping and risk of recurrence profiling Read More

kevin2020-12-10T13:30:24-08:00December 10th, 2020|News, Uncategorized|

Prediction of benefit from adjuvant pertuzumab by BluePrint RNA sequencing in the APHINITY trial
Prediction of benefit from adjuvant pertuzumab by BluePrint RNA sequencing in the APHINITY trial

Evidence

Prediction of benefit from adjuvant pertuzumab by BluePrint RNA sequencing in the APHINITY trial

PUBLICATION: SABCS 2020 AUTHORS:Ian E Krop, Lorenza Mittempergher, Joseph N Read More

kevin2021-03-08T16:46:34-08:00December 10th, 2020|Evidence|

Results from APHINITY Trial using BluePrint as a Biomarker Assay Presented at SABCS in Poster Spotlight Discussion

Agendia and Roche evaluate BluePrint’s stratification of HER2+ early breast Read More

kevin2020-12-10T06:02:31-08:00December 10th, 2020|News|

Agendia Presents Broad Spectrum of Data from FLEX Study Highlighting Tumor Heterogeneity within Underrepresented or Underserved Patient Populations at SABCS 2020

Agendia shares subgroup analyses from the first of its kind, Read More

kevin2020-12-09T13:58:43-08:00December 9th, 2020|News|

About kevin

Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification

The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stagebreast cancer

Using BluePrint to elucidate the molecular heterogeneity of triple negative breast cancers

The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in older patients

Prediction of benefit from adjuvant pertuzumab by BluePrint RNA sequencing in the APHINITY trial

Our Tests
Resources
Landmark Trials
Order A Test
For Patients

Christy Garcia

PROF. LAURA VAN ‘T VEER, PhD

ROOPOM BANERJEE

Salesforce Administrator

Network Administrator

Molecular Oncology Specialist

Molecular Oncology Specialist

Molecular Oncology Specialist

Salesforce Administrator Irvine, CA
Location: Irvine, CA Department: Information Technology Reports To: Director, Medical…

Network Administrator Irvine, CA
Location: Irvine, CA Department: IT Reports To: IT Ops Manager FLSA Status: Exempt…

Molecular Oncology Specialist FL
Location: Miami, FL Department: Sales Reports To: Regional Sales Director FLSA Status: Exempt…

Molecular Oncology Specialist Tampa, FL
Location: Tampa, FL Department: Sales Reports To: Regional Sales Director FLSA Status: Exempt…